MIRA Pharmaceuticals

Historical price data

MIRA Pharmaceuticals is a clinical-stage company developing novel oral analogs of ketamine (Ketamir-2) and marijuana (MIRA-55) for neurologic and neuropsychiatric disorders. Its key achievement is securing a preliminary DEA review stating its lead candidates are not considered controlled substances, which could significantly reduce regulatory and commercial hurdles. The strategy focuses on molecular modification to enhance oral bioavailability and therapeutic windows for large, underserved markets like treatment-resistant depression and neuropathic pain. With a valuation of ~$40M and its programs in preclinical/Phase 1 stages, MIRA represents a high-risk, high-potential investment in next-generation neuroscience therapeutics.

A molecular engineering platform focused on creating novel oral analogs of ketamine and cannabinoids with enhanced bioavailability, improved therapeutic windows, and non-controlled substance status.

Faces intense competition from approved drugs (e.g., Spravato®), generic ketamine, and large pharma pipelines in depression and dementia. Differentiation hinges on proving superior oral bioavailability and a cleaner side-effect profile while leveraging a non-controlled substance status.